CDKN1B and breast cancer: Miller et al. demonstrated that breast cancer cells overexpressing miR-221 or miR-222 had greater viability in the presence of TAM, and postulated that this conferred resistance to TAM through downregulation and loss of the effector molecule p27Kip1 [25].